Medidata Solutions announced that Omnicare Clinical Research has received Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win program for CROs and other service providers.
As a Rave Accredited Plus partner, Omnicare-which joined the ASPire to Win program back in January-broadens its EDC-related services. It can now offer its customers end-user training, study build, reporting, outputs, integration, and migration services for the Medidata Rave platform.
“From large, global pharmaceutical companies to specialty biotechs, our customers continue to view Medidata Rave as a critical component of the clinical development process and rely on the solution as a hub of clinical data,” said Michael Burton, Director of eClinical Solutions at Omnicare Clinical Research. “The ASPire to Win program has been instrumental in allowing us to easily and efficiently meet our customers’ needs for EDC at all phases of clinical trials.”
Medidata first announced ASPire to Win in April 2005.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.